Les Laboratoires Servier

Adir Et Compagnie

Les Laboratories Servier

Centre National De La Recherche Scientifique

Les Laboratories Server

L'institut National Des Sciences Appliquées De Rouen

L'universite De Rouen

Philippe Gloanec

Alain Rupin

Guillaume De Nanteuil

Tony Verbeuren

Marie-Odile Vallez

Bernard Portevin

Serge Simonet

Jean-Gilles Parmentier

Philippe Mennecier

Alain Benoist

Christine Lila

Patricia Sansilvestri-Morel

Arnaud-Pierre Schaffner

Michel Laubie

Mark Millan

Anne-Françoise Guillouzic

Alain Gobert

Jean-Claude Ortuno

Christine Courchay

Clotilde Mannoury La Cour

Jean-Charles Quirion

Philippe Jubault

Nicolas Boyer

Compounds of formula (I) wherein: Medicinal products containing the same which are useful in treating conditions requiring a TAFIa inhibitor.

Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I) wherein:Akrepresents an alkyl chain,X represents &#x2014;(CH)&#x2014;, &#x2014;CH(R)&#x2014;, &#x2014;N(R)&#x2014;, &#x2014;CH&#x2014;N(R)&#x2014;, &#x2014;N(R)&#x2014;CH&#x2014; or &#x2014;CH&#x2014;N(R)&#x2014;CH&#x2014;, Medicinal products containing the same which are useful in treating conditions requiring a TAFIa inhibitor.

Compounds of formula (I): wherein:  Medicinal products containing the same which are useful in treating and/or preventing thrombotic events.

2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I):(A)&#xb7;(B)&#x2003;&#x2003;(I)wherein A represents an angiotensin-converting enzyme inhibitor compound containing at least one salt-forming basic function, B represents a compound containing at least one salt-forming acid function and at least one NO donor group, m represents the number of acid functions of B that have been converted to a salt and n represents the number of basic functions of A that have been converted to a salt,the bond or bonds between A and B being of the ionic type. Medicinal products containing the same which are useful in treating cardiovascular pathologies.

Addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them

Compound of formula (I): wherein: represents 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4, Medicinal products containing the same which are useful as thrombin inhibitors.

4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds

A compound selected from those of formula (I): wherein: Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NKantagonist.

Indanyl-piperazine compounds

Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative

Bicyclic amino-pyrazinone compounds

2,3-methano-amino acid compounds

A compound selected from those of formula (I):

Compound of formula (I) ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent hydrogen or alkyl or alternatively R.sub.1 and R.sub.2 form, with the carbon atom which bears them, cycloalkyl,

Compounds derived from boronic acid

The invention relates to the compounds of formula (I): ##STR1## in which: R.sub.1 denotes hydrogen, acyl, alkoxycarbonyl, benzyloxycarbonyl, phenoxycarbonyl or linear or branched C.sub.1 -C.sub.6 alkyl, substituted or unsubstituted, or R.sub.6 SO.sub.2 -- in which R.sub.6 denotes alkyl, naphthyl, phenyl, benzyl or morpholine,

Peptide compounds derived from boronic acid

Growing community of inventors

Marly le roi, France

Philippe Gloanec